Overall, dual GLP-1/Gcg RAs have emerged as a promising therapeutic approach forcomprehensive cardiometabolic risk modification, especially in obesity andMASLD/MASH. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.